EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

doi:10.1158/1078-0432.CCR-15-3101

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2016

Gainor Justin F, Shaw Alice T, Sequist Lecia V, Fu Xiujun, Azzoli Christopher G, Piotrowska Zofia, Huynh Tiffany G, Zhao Ling, Fulton Linnea, Schultz Katherine R, Howe Emily, Farago Anna F, Sullivan Ryan J, Stone James R, Digumarthy Subba, Moran Teresa, Hata Aaron N, Yagi Yukako, Yeap Beow Y, Engelman Jeffrey A, Mino-Kenudson Mari

Abstract excerpt

PURPOSE: PD-1 inhibitors are established agents in the management of non-small cell lung cancer (NSCLC); however, only a subset of patients derives clinical benefit. To determine the activity of PD-1/PD-L1 inhibitors within clinically relevant molecular subgroups, we retrospectively evaluated response patterns among EGFR-mutant, anaplastic lymphoma kinase (ALK)-positive, and EGFR wild-type/ALK-negative patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to B7-H1 Antigen

Share to Lymphocytes, Tumor-Infiltrating

Share to Programmed Cell Death 1 Receptor

Share to Receptor Protein-Tyrosine Kinases

Share to Tomography, X-Ray Computed

Share to Translocation, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 27225694
DOI: 10.1158/1078-0432.CCR-15-3101
PMCID: PMC5026567

Genes

EGFR
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.PMID 27225694Read ↗

Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.Semantic proximity Read ↗

Revisiting Biomarker-Guided Therapy in EGFR-Mutant Non-Small Cell Lung Cancer with High PD-L1 Expression.Semantic proximity Read ↗

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.Semantic proximity Read ↗

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.Semantic proximity Read ↗

PD-1/PD-L1 Axis in Lung Cancer.Semantic proximity Read ↗

PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.Semantic proximity Read ↗

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.Semantic proximity Read ↗

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.Semantic proximity Read ↗

Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors.Semantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.